Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

BACKGROUND: This phase I/II trial evaluated the maximum tolerated dose (MTD) and pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide monotherapy (T) in patients with recurrent glioblastoma (GBM). M...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Reardon, David A., Nabors, Louis B., Mason, Warren P., Perry, James R., Shapiro, William, Kavan, Petr, Mathieu, David, Phuphanich, Surasak, Cseh, Agnieszka, Fu, Yali, Cong, Julie, Wind, Sven, Eisenstat, David D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2015
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4483093/
https://ncbi.nlm.nih.gov/pubmed/25140039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou160
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi